KRAS and adenocarcinoma: Limited evidence suggests possible co-expression of ERβ with ALK-EML4 fusions (single case report) [43], while KRAS-mutant adenocarcinomas frequently exhibit ERβ expression [44] - though these observations require larger clinical validation.